|
|
|
| This article has been cited by | | 1 | Availability of anticancer medicines in public and private sectors, and their affordability by low, middle and high-income class patients in Pakistan | | | Muhammad Rehan Sarwar,Sadia Iftikhar,Anum Saqib | | BMC Cancer.2018;18(1) | | [DOI] | | | 2 | Cost analysis of various branded versus generic chemotherapeutic agents used for the treatment of early breast cancer- a deep insight from India | | | Ananth Kashyap,M N Balaji,Manik Chhabra,Muhammed Rashid,Pradeep M Muragundi | | Expert Review of Pharmacoeconomics & Outcomes Research.2019;18(1)1 | | [DOI] | | | 3 | A comparison of asparaginase activity in generic formulations of
E.coli
derived L- asparaginase: In-vitro study and retrospective analysis of asparaginase monitoring in pediatric patients with leukemia | | | Hari Sankaran,Soumika Sengupta,Vaitashi Purohit,Anand Kotagere,Nirmalya Roy Moulik,Maya Prasad,Chetan Dhamne,Gaurav Narula,Shripad Banavali,Vikram Gota | | British Journal of Clinical Pharmacology.2020;86(6)1081 | | [DOI] | |
|
